Y. Ning

发表

Accelerated approval of oncology products: the food and drug administration experience.

P. Keegan, R. Pazdur, R. Justice, 2011, Journal of the National Cancer Institute.

Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab

J. Aragon-Ching, W. Dahut, Y. Ning, 2008, Acta oncologica.

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

P. Keegan, R. Pazdur, R. Justice, 2011, The New England journal of medicine.

Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

R. Pazdur, Todd R. Palmby, Lijun Zhang, 2013, Clinical Cancer Research.

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

S. Steinberg, J. Trepel, W. Figg, 2016, BJU international.

U.S. FDA Approval Summary: Abiraterone Acetate

R. Pazdur, Todd R. Palmby, Lijun Zhang, 2013 .

FDA Approval of Prostate Cancer Treatments

R. Pazdur, R. Dagher, Y. Ning, 2010 .

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.

S. Steinberg, H. Parnes, M. Raffeld, 2020, The Lancet. Oncology.

Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.

S. Steinberg, H. Parnes, M. Bagheri, 2018 .

Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

H. Parnes, J. Wright, W. Figg, 2009, Cancer investigation.

Reversal of docetaxel resistance with bevacizumab and thalidomide.

W. Figg, W. Dahut, Y. Ning, 2009, Clinical genitourinary cancer.

Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC)

H. Parnes, A. Fojo, J. Wright, 2008 .

Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Dhananjay D. Marathe, R. Pazdur, Todd R. Palmby, 2013, Clinical Cancer Research.

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.

K. Goldberg, R. Pazdur, R. Sridhara, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

T. Fojo, S. Bates, J. Schlom, 2011, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

S. Steinberg, H. Parnes, J. Trepel, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutated -Metastatic Castrate Resistant Prostate Cancer.

M. Anscher, K. Goldberg, R. Pazdur, 2020, The oncologist.

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

K. Goldberg, Amy McKee, R. Pazdur, 2018, The oncologist.

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

K. Goldberg, R. Pazdur, Todd R. Palmby, 2017, The oncologist.

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Justin C. Earp, Amy McKee, R. Pazdur, 2014, Clinical Cancer Research.

A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors

S. Steinberg, S. Pal, A. Apolo, 2016 .

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

S. Steinberg, H. Parnes, M. Merino, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

T. Fojo, S. Bates, J. Schlom, 2010, Clinical Cancer Research.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

S. Steinberg, H. Parnes, J. Trepel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)

H. Parnes, J. Wright, W. Figg, 2007 .

A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC).

H. Parnes, J. Wright, W. Figg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

R. Pazdur, Geoffrey Kim, Lijun Zhang, 2015, The oncologist.

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

R. Fletterick, L. Neckers, R. Guy, 2011, Proceedings of the National Academy of Sciences.

846OFinal results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

S. Steinberg, H. Parnes, S. Pal, 2017 .

Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

Richard Pazdur, R. Pazdur, A. Murgo, 2014, Cancer.

Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

S. Steinberg, H. Parnes, J. Trepel, 2012 .

Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

S. Steinberg, H. Parnes, J. Trepel, 2012, Journal of Clinical Oncology.

Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.

V. E. Maher, Y. Ning, 2015, Urologic oncology.

A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

Laura B. Machado, S. Steinberg, H. Parnes, 2016 .

A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).

S. Steinberg, H. Parnes, M. Merino, 2014 .

A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.

S. Steinberg, H. Parnes, J. Wright, 2017 .

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

K. Goldberg, R. Pazdur, G. Blumenthal, 2017, The oncologist.

Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).

S. Steinberg, H. Parnes, M. Bagheri, 2018 .

Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.

R. Pazdur, R. Justice, R. Sridhara, 2007, Oncology.

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC).

H. Parnes, J. Wright, W. Figg, 2013 .